

PROVIDER BULLETIN

PROVIDER INFORMATION



April 3, 2023

Medical Policy Updates: Coupe Health and Self-Funded Benefit Plans managed by Blue Cross and Blue Shield of Alabama

Participating providers are invited to submit for consideration scientific, evidence-based information, professional consensus opinions, and other information supported by medical literature relevant to our draft policies for Coupe Health and Self-Funded benefit plans managed by Blue Cross and Blue Shield of Alabama.

The draft policies are available for physician comment for 45 days from the posting date found on the document. At the conclusion of the 45 days, policies will go into effect. Make sure your voice is heard by providing feedback directly to us.

How to Submit Comments on Draft Medical Policies

[Complete our medical policy feedback form](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback) online at <https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback> or send comments and supporting documentation to us by mail or fax:

Birmingham Service Center
Attn: Health Management - Medical Policy
P.O. Box 10527
Birmingham, AL 35202
Fax: 205-220-0878

Draft Medical Policies

Draft medical policies can be found at [Policies & Guidelines \(exploremyplan.com\)](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback)

Policy #	Policy Title
MP-387	Hematopoietic Cell Transplantation for Non-Hodgkin Lymphomas
MP-483	Transcatheter Aortic-valve Implantation for Aortic Stenosis
MP-170	Transcranial Magnetic Stimulation as a Treatment of Depression and Other Psychiatric Disorders
MP-753	Cardiac Contractility Modulation
MP-451	Intravitreal and Punctum Corticosteroid Implants
MP-718	Neuromuscular Electrical Stimulation (NMES)

Draft Provider-Administered Drug Policies

Draft provider-administered drug policies can be found at [Policies & Guidelines \(exploremyplan.com\)](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback) and [Policies & Guidelines \(exploremyplan.com\)](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback)

Policy #	Policy Title
PH-90006	Aldurazyme® (laronidase)

Policy #	Policy Title
PH-90299	Brineura (cerliponase alfa)
PH-90034	Elaprase® (idursulfase)
PH-90660	Enjaymo™ (sutimlimab-jome)
PH-90042	Fabrazyme® (agalsidase beta)
PH-90277	Kanuma™ (sebelipase alfa)
PH-90079	Lumizyme® (alglucosidase alfa)
PH-90346	Mepsevii® (vestronidase alfa-vjvk)
PH-90615	Nexviazyme™ (avalglucosidase alfa-ngpt)
PH-90089	Nplate® (romiplostim)
PH-90677	Skysona® (elivaldogene autotemcel)
PH-90673	Xenpozyme™ (olipudase alfa)
PH-9406	Rituxan, Truxima, Ruxience, Riabni, Rituxan Hycela (rituximab)
PH-90312	Injectafer® (ferric carboxymaltose injection)
PH-90524	Monoferric™ (ferric derisomaltose)
PH-90693	Briumvi™ (ublituximab-xiiy)
MPD-90691	Adstiladrin® (nadofaragene firadenovec-vncg)
PH-90694	Leqembi™ (lecanemab-irmb)
PH-90688	Hemgenix® (etranacogene dezaparvovec)
PH-90648	Rethymic® (Allogeneic processed thymus tissue)